JGHF Okuda State-of-the-Art Lecture

Selection of Lecturer

  • The APDW Federation nominates three (3) potential lecturers and appropriate topics.
  • The potential nominees should come from more than one country within Asia Pacific region.
  • The JGH Foundation will make the final decision on the selection of the lecturer in the year preceding the lecture.
  • The APDW Federation will advise the APDW Local Organising Committee who will notify the selected lecturer.


The funding package is to assist in covering the following expenses:

  • Return airfares economy for national sector and business class for international sector (or two economy class airfares for the full trip to equivalent cost) between home city and the venue for the APDW meeting.
  • Accommodation for the duration of APDW.
  • Honorarium of US$2,000 for submission of manuscript at the time of the meeting for publication in the Journal of Gastroenterology and Hepatology (JGH).
  • All travel and accommodation arrangements will be made by the APDW organisers.
  • The selected Lecturer must ensure that both a manuscript and all relevant receipts are provided to the APDW organisers to receive reimbursement and payment.


The JGHF Okuda State of the Art Lecturer is required to submit a manuscript at the time of the meeting that will cover the content of his/her lecture. The manuscript should be structured as a review article between 3,000-5,000 words and between 3-8 tables and figures. It is expected that this will be a detailed and learned exposé of the topic concerned, and will also emphasise practical points for clinicians and investigators. For information on JGH style guidelines please see the Wiley-Blackwell House Style Guide

Past Award Recipients

Year Recipient City Topic
2022 Ji-dong Jia Beijing Novel Diagnosis and Therapy for Autoimmune Liver Diseases
2021 Kazuichi Okazaki Osaka Current Perspectives on IgG4-Related Disease in Hepato-Gastroenterology
2019 Tooru Shimosegawa Sendai Clinical features and diagnosis of early-stage pancreatic cancer
2018 Henry Chan Hong Kong Challenges of Hepatitis B in the Era of Antiviral Therapy
2017 Ching Lung Lai Hong Kong Chronic Hepatitis B: HBsAg seroclearance, cccDNA and Treatment under Trial
2016 John Windsor Auckland Novel strategies for treating severe acute pancreatitis
2015 Edward Gane Auckland Advances in HCV Therapy- Towards a Global HCV Elimination
2014 Stephen Locarnini Melbourne New Therapeutic Targets Against Hepatitis B Virus: The Need for Molecular and Immune Based Treatments
2013 Fu-sheng Wang Beijing Immune disorders lead to liver damage and influence antiviral efficacy in patients with chronic HBV infection
2012 Jia-Horng Kao Taipei Risk stratification for HBV-related HCC, Jia Horng Kao, Taipei
2011 Mashashi Mizokami Chiba Optimising Treatment for Chronic Hepatitis C - incorporating molecular medicine into clinical practice
2010 Anna Suk-Fong Lok Michigan Does antiviral therapy for hep B & C prevent HCC?
2009 Ding-Shinn Chen Taipei Towards Elimination and Eradication of Hepatitis B
2008 Masashi Mizokami Nagoya Management of hepatocellular carcinoma; From surveillance to molecular targeted therapy.
2007 No award made
2006 Malcolm Alison London Stem Cell Therapy in Liver Diseases
2005 Sung-Gyu Lee Seoul Asian Contribution to living donor liver transplantation
2004 Daiming Fan Xian A bird’s-eye view on gastric cancer research of the past 25 years
2003 Shiu-Kum Lam Hong Kong The role of cyclo-oxygenase (COX) in GI Diseases
2002 Yun-Fan Liaw Taipei Hepatitis flares and HBeAg seroconversion: Implications in anti-HBV